Cost analysis of “bridging therapy” with low-molecular-weight heparin versus unfractionated heparin during temporary interruption of chronic anticoagulation
- 15 February 2004
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 93 (4) , 509-511
- https://doi.org/10.1016/j.amjcard.2003.10.060
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Dalteparin as Periprocedure Anticoagulation for Patients on Warfarin and at High Risk of ThrombosisAnnals of Pharmacotherapy, 2001
- Perioperative Management of the Chronically Anticoagulated PatientJournal of Thrombosis and Thrombolysis, 2001
- Safety and cost of low-molecular-weight heparin as bridging anticoagulant therapy in subacute cerebral ischemia.Stroke, 2000
- Low Molecular Weight Heparin After Mechanical Heart Valve ReplacementCirculation, 2000
- Use of enoxaparin for the chronically anticoagulated patient before and after proceduresThe American Journal of Cardiology, 1999
- Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis: A Cost-Effectiveness AnalysisAnnals of Internal Medicine, 1999